Oyster Point Outlines Restructuring Plan With Savings Of Up To $48M In 2023

• Oyster Point Pharma Inc (NASDAQ: OYST) will implement an operating expense streamlining plan to reduce employee and non-employee expenses (up to 50 roles) across the organization.

• The company plans to continue to drive the launch of Tyrvaya with approximately 150-200 field-based sales resources.

• The plan is expected to reduce operating expenses by approximately $6 million - $8 million in 2H of 2022 and approximately $40 million - $48 million in 2023.

• Related: FDA Approves First Nasal Spray For Dry Eye Disease From Oyster Point Pharma.

• To reflect these strategic priorities, the company is also announcing that Daniel Lochner, its current CFO, will take on additional responsibilities now, serving in a dual role as the CFO and Chief Business Officer.

• The company will focus its R&D efforts on OC-01 (varenicline solution) nasal spray to target stage 1 neurotrophic keratopathy and Enriched Tear Film (ETF) gene therapy to target stages 2 and 3 neurotrophic keratopathy.

• The company expects study results for the OLYMPIA Phase 2 clinical trial for Stage 1 Neurotrophic Keratopathy during Q4 of 2022.

• The company has submitted a Pre-IND meeting request to the FDA regarding the ETF Gene Therapy program and expects to hold the meeting during 2H of 2022.

• Price Action: OYST shares closed lower by 7.16% at $4.67 on Tuesday.

See more from Benzinga

• 89bio Posts Promising Pegozafermin Data For Severe Hypertriglyceridemia

• JMP Views Positive Phase 3 Data Equivalent To 'Schizophrenia Blockbuster' For This Stock

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.